mktcap_usd=313494
ConsensRecom=1.92
earning_yield=1.78%
growth=4.94%
dilution=-2.67%
div_ratio=40.08%
sh_payout_ratio=100.00%
margin=18.72%
cfmargin=12.30%
ratiopaid=38.79%
sratiopaid=8.58%
ratioConsens=1.16
Description
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.
Income and Cashflow Statements USD
| EndDate | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | mean | std |
|---|---|---|---|---|---|---|---|---|---|
| sourceDate | 2017-02-22 | 2020-02-19 | 2020-02-19 | 2020-02-19 | 2021-02-17 | 2022-02-23 | 2023-02-22 | NaN | NaN |
| period | 12M | 12M | 12M | 12M | 12M | 12M | 12M | NaN | NaN |
| rev | 21222 | 19974 | 21493 | 22320 | 24540 | 28318 | 28541 | 23773 | 3470 |
| revgrowth | NaN | -6.06% | 7.33% | 3.77% | 9.48% | 14.32% | 0.78% | 4.94% | 7.13% |
| earn | 2738 | -204 | 3232 | 8318 | 6194 | 5582 | 6245 | 4586 | 2842 |
| earnx | 2738 | 4494 | 3326 | 4638 | 6194 | 5582 | 6245 | 4745 | 1364 |
| margin | 12.90% | -1.02% | 15.04% | 37.27% | 25.24% | 19.71% | 21.88% | 18.72% | 11.80% |
| xmargin | 12.90% | 22.50% | 15.47% | 20.78% | 25.24% | 19.71% | 21.88% | 19.78% | 4.25% |
| earningyld | 3.27% | -0.22% | 2.57% | 6.43% | 3.82% | 2.11% | 1.85% | 2.83% | 2.04% |
| cfop | 4851 | 5616 | 5524 | 4837 | 6500 | 7261 | 7084 | 5953 | 1004 |
| cfinv | -3139 | -3784 | 1906 | -8083 | -2259 | -2762 | -3262 | -3055 | 2921 |
| cffin | -560 | 143 | -5905 | -2324 | -3137 | -4131 | -5407 | -3046 | 2302 |
| cfopmargin | 22.86% | 28.11% | 25.70% | 21.67% | 26.49% | 25.64% | 24.82% | 25.04% | 2.18% |
| cfinvmargin | -14.79% | -18.94% | 8.87% | -36.21% | -9.21% | -9.75% | -11.43% | -13.07% | 13.44% |
| cffinmargin | -2.64% | 0.71% | -27.47% | -10.41% | -12.78% | -14.59% | -18.94% | -12.30% | 9.54% |
| shares | 1118 | 1108 | 1088 | 985 | 961 | 960 | 952 | 1024 | 76.0 |
| fx | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0 |
| price | 74.9 | 83.0 | 116 | 131 | 169 | 276 | 355 | 172 | 105 |
| dilution | NaN | -0.93% | -1.76% | -9.96% | -2.51% | -0.09% | -0.78% | -2.67% | 3.67% |
| dividend | 2158 | 2192 | 2312 | 2410 | 2687 | 3087 | 3536 | 2626 | 516 |
| sharebb | NaN | 814 | 1920 | 12747 | 3664 | 193 | 2346 | 3614 | 4635 |
| ltdebtbb | NaN | -1573 | 744 | -4622 | -2769 | 1240 | 609 | -1062 | 2332 |
| mgtbb | NaN | 1576 | -929 | 8211 | 445 | 389 | 1084 | 1796 | 3254 |
| divyld | 2.58% | 2.39% | 1.84% | 1.86% | 1.66% | 1.16% | 1.05% | 1.79% | 0.57% |
| sharebbyld | NaN | 0.93% | 1.76% | 9.96% | 2.51% | 0.09% | 0.78% | 2.67% | 3.67% |
| mgtyld | NaN | 1.72% | -0.74% | 6.34% | 0.27% | 0.15% | 0.32% | 1.34% | 2.57% |
Balance Sheet
| EndDate | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | mean | std |
|---|---|---|---|---|---|---|---|---|---|
| sourceDate | 2017-02-22 | 2020-02-19 | 2020-02-19 | 2020-02-19 | 2021-02-17 | 2022-02-23 | 2023-02-22 | NaN | NaN |
| mktcap | 83721 | 91875 | 125927 | 129465 | 162196 | 265111 | 338078 | 170911 | 95293 |
| mktcapgrowth | NaN | 9.29% | 31.53% | 2.77% | 22.54% | 49.13% | 24.31% | 23.26% | 16.46% |
| totAsset | 38806 | 44981 | 43908 | 39286 | 46633 | 48806 | 49490 | 44559 | 4246 |
| assetgrowth | NaN | 14.77% | -2.41% | -11.12% | 17.14% | 4.55% | 1.39% | 4.05% | 10.64% |
| curAsset | 15101 | 19202 | 20550 | 13710 | 17462 | 18452 | 18034 | 17502 | 2363 |
| curAssetPct | 38.92% | 42.69% | 46.80% | 34.90% | 37.45% | 37.81% | 36.44% | 39.29% | 4.11% |
| totLiab | 24798 | 33389 | 34080 | 36679 | 40992 | 39827 | 38840 | 35515 | 5514 |
| totLiabPct | 63.90% | 74.23% | 77.62% | 93.36% | 87.90% | 81.60% | 78.48% | 79.59% | 9.51% |
| curLiab | 10987 | 14536 | 11888 | 11775 | 12482 | 15053 | 17138 | 13408 | 2221 |
| curLiabPct | 28.31% | 32.32% | 27.07% | 29.97% | 26.77% | 30.84% | 34.63% | 29.99% | 2.87% |
| ltDebt | 8368 | 9940 | 9196 | 13818 | 16587 | 15346 | 14738 | 12570 | 3318 |
| ltDebtPct | 21.56% | 22.10% | 20.94% | 35.17% | 35.57% | 31.44% | 29.78% | 28.08% | 6.45% |
| Equity | 14008 | 11592 | 9829 | 2607 | 5642 | 8979 | 10650 | 9044 | 3815 |
| EquityPct | 36.10% | 25.77% | 22.38% | 6.64% | 12.10% | 18.40% | 21.52% | 20.41% | 9.51% |
| PB | 5.98 | 7.93 | 12.8 | 49.7 | 28.7 | 29.5 | 31.7 | 23.8 | 15.7 |
Beta
len=92.0
mean=19.40%
sd=22.86%
alpha=2.22%
beta=31.92%
r_sq=5.37%
lastdate=2023-03-17
firstdate=2016-05-31
logret1y=13.93%
Financial Snapshot
CompanyName=Eli Lilly And Co
ID=1
Name=Ordinary Shares
Ticker=LLY
ISIN=None
RIC=LLY
DisplayRIC=LLY.N
InstrumentPI=290816
QuotePI=1090569
InstrumentPermID=8590943610
QuotePermID=55838323825
Exchange=New York Stock Exchange
ExchangeCode=NYSE
ExchangeCountry=USA
CoStatus=Active
CoType=Equity Issue
LastModified=2023-02-22
LatestAvailableAnnual=2022-12-31
LatestAvailableInterim=2022-12-31
Employees=39000
SharesOut=952347126
TotalFloat=948746136
ReportingCurrency=USD
MostRecentExchange=1.0
Industry=Pharmaceuticals (NEC)
IndustryCode=5620104010
NPRICE=329
NHIG=384
NLOW=277
PDATE=2023-03-17
VOL10DAVG=4.25
EV=327520
MKTCAP=313494
AREV=28541
AEBITD=9803
ANIAC=6245
AEPSXCLXOR=6.91
AREVPS=31.6
ABVPS=11.2
ACSHPS=2.33
ACFSHR=8.60
ADIVSHR=3.92
AGROSMGN=76.8
AROEPCT=63.6
APR2REV=11.0
APEEXCLXOR=47.6
APRICE2BK=29.4
ConsRecom=1.92
TargetPrice=382
ProjLTGrowthRate=22.9
ProjPE=38.7
ProjSales=30630
ProjSalesQ=6853
ProjEPS=8.50
ProjEPSQ=1.81
ProjProfit=7674
ProjDPS=4.36
quoteccy=USD
quotefx=100.00%
exchgccy=USD
exchgfx=100.00%
tick=None
exchg=None
Valuation
ticker=LLY
exchg=AMEX
RIC=LLY
CompanyName=Eli Lilly And Co
ExchangeCode=NYSE
Industry=Pharmaceuticals (NEC)
IndustryCode=5620104010
sector=56 Healthcare
region=us
ccy=USD
fx=100.00%
mktcap_usd=313494
float_usd=312308
ConsensRecom=1.92
earning_yield=1.78%
growth=4.94%
dilution=-2.67%
margin=18.72%
searning_yield=0.74%
sgrowth=-1.57%
smargin=7.80%
sdilution=0.68%
projearning_yield=2.55%
earning_excl_yield=2.08%
div_ratio=40.08%
bb_ratio=1.49
sh_payout_ratio=100.00%
PS=10.4
price=329
ratio=38.79%
sratio=8.58%
sratiopaid=8.58%
ratioConsens=1.16
turnover=53.31%
cfmargin=12.30%
rdmargin=24.80%
scfmargin=3.47%
quoteccy=USD
quotefx=100.00%
ratiopaid=38.79%
dt=2023-03-17
assetgrowth=4.05%
dlnfx=0